| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Proceeds from 2025 convertible note, net | 4,913 | - |
| Net cash provided by financing activities | 16,931 | 10,487 |
| Effect of foreign currency on cash | -2 | - |
| Net change in cash and cash equivalents | 4,948 | 2,369 |
| Cash and cash equivalents at beginning of period | 3,672 | - |
| Cash and cash equivalents at end of period | 8,620 | - |
Serina Therapeutics, Inc. (SER)
Serina Therapeutics, Inc. (SER)